Michael Ackermann, PhD

Michael Ackermann is Chairman of Oyster Point Pharmaceuticals, Inc., Chairman of Tarsus Pharmaceuticals, Inc. and Chairman of Presidio Medical, Inc. Michael is also teaching faculty at Stanford University’s Biodesign graduate program. Prior, Michael served as Vice President, Neurostimulation for Allergan, plc after serving as CEO of Oculeve, Inc., which was acquired by Allergan in August 2015. He received a bachelor’s degree in biomedical engineering from Vanderbilt University, M.S. and Ph.D. degrees in biomedical engineering from Case Western Reserve University is a graduate of the Stanford University Biodesign Fellowship, and Vision Research Fellowship at Stanford.